title: [Invasive treatment of hypertension : Update 2016].
abstract: Invasive treatment methods-more specifically renal denervation and baroreceptor activator therapy-have been used for the treatment of therapy-resistant hypertension for several years now. In particular, renal denervation has aroused great interest because it was easy to perform and the first studies provided very promising results. Meanwhile, however, three randomized, blinded studies have been published, and none showed a significant benefit of renal denervation compared to a sham procedure. In addition, in several studies it was demonstrated that intensification of drug therapy, particularly with spironolactone, is at least comparable. Carotid sinus node baroreceptor activator therapy tends to be superior to renal denervation, but the probe currently used is not optimal. The first results by inserting an arteriovenous shunt between the iliac artery and vein are promising, but lack long-term safety data. Currently, all invasive treatment procedures should be performed within the framework of studies or accurate register surveys.
authors: Klinik für Nieren- und Hochdruckerkrankungen, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland. menne.jan@mh-hannover.de.
authors: J
authors: J
authors: Menne
authors: Klinik für Kardiologie und Pneumologie und Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Universität Göttingen, Göttingen, Deutschland.
authors: R
authors: R
authors: Wachter
mesh_terms: D000959:Antihypertensive Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy / Q000379:methods; D004599:Electric Stimulation Therapy / Q000379:methods*; D019317:Evidence-Based Medicine; D006801:Humans; D006973:Hypertension / Q000175:diagnosis* / Q000628:therapy*; D007668:Kidney / Q000294:innervation* / Q000601:surgery; D013562:Sympathectomy / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents
keywords: Arteriovenous shunt; Baroreceptors; Denervation, renal; Drug resistance, hypertension; Spironolactone